CST6

Across TCGA pan-cancer cohorts, CST6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CST6 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CST6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CST6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where CST6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.874	0.606	.001	31	view →
LUAD	DFS	Tertile	III,IV	0.400	0.937	.006	19	view →
UCEC	OS	Median	All	0.798	1.000	.011	10	view →
PDAC	OS	Median	III,IV	0.489	0.877	.039	2	view →
LSCC	OS	Tertile	All	0.734	0.910	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CST6–CCRCC (DFS)

Open the CCRCC breakdown →